**Supplementary Table 1.** Mortality outcomes among the combined AMBITION and ACTA participants with HIV-associated cryptococcal meningitis stratified by ART status at the time of presentation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **ART status** | **2-week mortality**\* |  | **10-week mortality**\* |  |
|  | Mortality risk (95% CI) | N | Risk ratio (95% CI) | Mortality risk (95% CI) | N | Risk ratio (95% CI) |
| A. |  |  |  |  |  |  |
| Not on ART | 15.7% (13.0-18.3) | 111/707 | Base | 30.2% (26.8-33.6) | 214/707 | Base |
| On ART | Overall | 16.0% (13.4-18.5) | 125/777 | 1.00 (0.9 – 1.3) | 32.5% (29.2-35.8) | 255/777 | 1.06 (0.9 - 1.2) |
|  |  *≤14 days* |  *21.5% (14.2-28.8)* | *26/120* | *1.37 (0.9 – 2.0)* |  *36.0% (27.6-44.3)* |  *44/120* | *1.19 (0.9 – 1.5)* |
|  |  *>14 days ≤2 months* |  *13.8% (7.9-19.7)* | *18/130* | *0.88 (0.6 – 1.4)* |  *30.8% (22.9-38.7)* |  *40/130* | *1.02 (0.8 – 1.3)* |
|  |  *>2 months ≤6 months* |  *7.3% (2.1-12.5)* |  *7/92* | *0.47 (0.2 – 1.0)* |  *23.3% (14.8-31.8)* |  *22/92* | *0.77 (0.5 – 1.1)* |
|  |  *>6 months* |  *16.7% (12.4-20.9)* | *50/307* | *1.06 (0.8 – 1.4)* |  *33.5% (28.2-38.9)* |  *101/307* | *1.11 (0.9 – 1.3)* |
|  | ART: antiretroviral therapy; CI: confidence interval.\* Mortality risk derived from the generalized linear model adjusted for treatment  |  |